RenovoRx (RNXT) Projected to Announce Earnings on Thursday

RenovoRx (NASDAQ:RNXT) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect RenovoRx to announce earnings of ($0.05) per share and revenue of $1.06 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

RenovoRx (NASDAQ:RNXT) last posted its earnings results on Wednesday, August 12th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.02. The company had revenue of $0.91 million for the quarter, compared to the consensus estimate of $0.70 million. RenovoRx had a negative return on equity of 135.11% and a negative net margin of 621.71%. On average, analysts expect RenovoRx to post ($0.24) EPS for the current fiscal year and ($0.12) EPS for the next fiscal year.

RenovoRx Stock Performance

Shares of NASDAQ RNXT traded up $0.01 during trading hours on Wednesday, reaching $1.30. 43,969 shares of the stock were exchanged, compared to its average volume of 455,600. The firm has a market capitalization of $58.89 million, a price-to-earnings ratio of -4.21 and a beta of 1.12. The stock’s fifty day simple moving average is $1.56 and its 200 day simple moving average is $1.11. RenovoRx has a 52 week low of $0.70 and a 52 week high of $2.59.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on RNXT. Wall Street Zen raised RenovoRx from a “sell” rating to a “hold” rating in a report on Sunday. Weiss Ratings upgraded RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.50.

About RenovoRx

RenovoRx, Inc is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue.

RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.